Alcon ACL

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. New Morningstar Analyst Report for Novartis AG

      Stock Reports

      Thu, 21 Aug 2014

      5 billion exemplifies Novartis' aggressive bids for strong strategic assets. Further, the much larger acquisition of Alcon in the rapidly growing eye-care market for just over $50 billion shows that the company will aggressively reinvest capital

    2. European Commission approves Alcon combo drug for reducing IOP

      Headlines

      Mon, 28 Jul 2014

      The European regulator approves Sandoz' (NYSE: NVS ) Simbrinza eye drops suspension ( brinzolamide 10 mg/ml and brimonidine tartrate 2mg/ml) to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for which monotherapy provides insufficient IOP ...

    3. Novartis says Alcon glaucoma treatment approved in EU

      Headlines

      Mon, 28 Jul 2014

      ZURICH, July 28 (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon 's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

    4. Update: Google Teaming Up With Novartis To Develop Smart Lenses

      Headlines

      Fri, 18 Jul 2014

      conditions. Novartis' eye care division Alcon has entered into an agreement with ..... solutions to big global problems, so that Alcon can properly utilize the opportunity ..... technology. The technology could enhance Alcon 's eye care pipeline and strengthen

    5. Novartis' (NVS) CEO Joe Jimenez on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 17 Jul 2014

      Chief Executive Officer Harry Kirsch - Chief Financial Officer David Epstein - Head of the Pharma Division Jeff George - Alcon Richard Francis - Sandoz Samir Shah - Global Head, IR Analysts Graham Parry - Bank of America Merrill Lynch Richard Vosser

    6. More on Novartis Q2 results

      Headlines

      Thu, 17 Jul 2014

      1.0%); Pharmaceuticals: $8,199M (+1.0%); Alcon : $2,817M (+3.0%); Sandoz: $2,331M (+5 ..... Pharmaceuticals Growth: in line with 2013 (unch); Alcon Growth: Mid to high-single digit (unch); Sandoz Growth

    7. Novartis Posts Slightly Weak 2Q, but Margin Gains From Restructurings Reinforce Wide Moat

      Commentary

      Thu, 17 Jul 2014

      psoriasis drug AIN457 and hypertension drug LCZ696) will largely offset the patent losses. Novartis' eye-care business ( Alcon ) and generics unit (Sandoz) should help mitigate the patent losses as well.

    8. Alcon to license Google technology

      Headlines

      Tue, 15 Jul 2014

      Novartis (NYSE: NVS ) unit Alcon enters an agreement with Google (NASDAQ: GOOG ) to in-license its "smart lens" technology for all ocular medical uses. Alcon intends to develop the technology to transform eye care and ultimately

    9. Novartis to license Google "smart lens" technology for Alcon

      Headlines

      Tue, 15 Jul 2014

      ZURICH, July 15 (Reuters) - Novartis said it has struck an agreement with Google for its eyecare unit Alcon to license the American technology firm's smart lens technology for medical use.

    10. Novartis Posts Slightly Weak 1Q as Generics Weigh on Growth, but No Fair Value Change

      Commentary

      Thu, 24 Apr 2014

      be facing increased competition over the next several quarters. Outside the drug group, both the eye-care division of Alcon and the generic division of Sandoz posted gains of 6% and 4%, respectively, versus the prior-year period. We expect

    « Prev12345Next »
    Content Partners